## Paul H Naylor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11646683/publications.pdf

Version: 2024-02-01

567281 580821 47 747 15 25 citations h-index g-index papers 48 48 48 367 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Increase of cyclic GMP induced in murine thymocytes by thymosin fraction 5. Biochemical and Biophysical Research Communications, 1976, 73, 843-849.	2.1	58
2	Immunochemical studies on thymosin: Radioimmunoassay of thymosin $\hat{l}^2$ 4. Immunopharmacology, 1984, 7, 9-16.	2.0	55
3	Thymosin $\hat{l}\pm 1$ and thymosin $\hat{l}^24$ in serum: Comparison of normal, cord, homosexual and AIDS serum. International Journal of Immunopharmacology, 1986, 8, 667-676.	1.1	50
4	Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunology, Immunotherapy, 2012, 61, 771-782.	4.2	39
5	Isolation of thymosin $\hat{l}\pm 1$ from thymosin fraction 5 of different species by high-performance liquid chromatography. Journal of Chromatography A, 1983, 266, 533-544.	3.7	33
6	Immune response and epitope mapping of a candidate hiv-1 p17 vaccine hgp30. Journal of Clinical Laboratory Analysis, 1990, 4, 43-47.	2.1	31
7	Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine — HGP-30-KLH. International Journal of Immunopharmacology, 1991, 13, 117-127.	1.1	28
8	Thymic Physiology and Biochemistry. Advances in Clinical Chemistry, 1987, 26, 203-292.	3.7	24
9	Circulating thymulin and thymosin- $\hat{l}\pm 1$ activity in pediatric acquired immune deficiency syndrome: In vivo and in vitro studies. Journal of Pediatrics, 1986, 109, 422-427.	1.8	23
10	Low Thymosin Alpha-1 Concentrations in Patients Chronically Infected with the Hepatitis B Virus*. Viral Immunology, 1991, 4, 195-199.	1.3	23
11	Thymosin: Cyclic nucleotides and T cell differentiation. Life Sciences, 1979, 25, 301-309.	4.3	22
12	THYMOSIN IN THE EARLY DIAGNOSIS AND TREATMENT OF HIGH RISK HOMOSEXUALS AND HEMOPHILIACS WITH AIDS-LIKE IMMUNE DYSFUNCTION. Annals of the New York Academy of Sciences, 1984, 437, 88-97.	3.8	20
13	Effect of calcium on the cyclic GMP elevation induced by thymosin fraction 5. Biochemical and Biophysical Research Communications, 1979, 90, 810-818.	2.1	19
14	MicroELISA method for measurement of human serum thymosin $\hat{l}\pm 1$ . Journal of Immunological Methods, 1985, 80, 45-53.	1.4	19
15	T cell targeted immune enhancement yields effective T cell adjuvants. International Immunopharmacology, 2003, 3, 1205-1215.	3.8	19
16	Diminished thymosin <sub>alphaâ€1</sub> levels in persons exposed to 2,3,7,8â€tetrachlorodibenzoâ€ <i>p</i> current Issues, 1989, 28, 285-295.	2.3	16
17	Immunopharmacology of Thymosin $\hat{l}\pm 1$ and Cytokine Synergy. Annals of the New York Academy of Sciences, 2007, 1112, 235-244.	3.8	16
18	Effect of thymosin and lipopolysaccharide on murine lymphocyte cyclic AMP. Journal of Immunological Methods, 1978, 20, 143-153.	1.4	15

#	Article	IF	CITATIONS
19	Effect of Peptide-Carrier Coupling on Peptide-Specific Immune Responses. Immunobiology, 2001, 203, 601-615.	1.9	15
20	Thymosins and anti-thymosins: Properties and clinical applications. Medical Oncology and Tumor Pharmacotherapy, 1986, 3, 211-21.	1.1	15
21	Inverse correlation between age related abnormalities of Tâ€cell immunity and circulating thymosin α <sub>1</sub> levels in haemophilia A. British Journal of Haematology, 1984, 58, 325-336.	2.5	13
22	Improved ELISA to measure thymosin $\hat{l}\pm 1$ : Comparison of whole and absorbed antisera. International Journal of Immunopharmacology, 1988, 10, 795-801.	1.1	13
23	Changes in circulating levels of neuroendocrine and thymic hormones during aging in rats: A correlation study. Experimental Gerontology, 1990, 25, 149-157.	2.8	12
24	Thymosin- $\hat{l}\pm 1$ , but not interferon- $\hat{l}\pm$ , specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells. Journal of Hepatology, 1996, 25, 814-820.	3.7	12
25	IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Vaccine, 2010, 28, 7054-7062.	3.8	12
26	Peptide Based Vaccine Approaches for Cancerâ€"A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen. Cancers, 2011, 3, 3991-4009.	3.7	12
27	Thymosin $\hat{l}^24$ synergizes with human granulocyte-macrophage colony-stimulating factor in maintaining bone marrow proliferation. Immunopharmacology, 1993, 26, 83-92.	2.0	11
28	CYTOKINE-MEDIATED APOPTOSIS AND INHIBITION OF VIRUS PRODUCTION AND ANCHORAGE INDEPENDENT GROWTH OF VIRAL TRANSFECTED HEPATOBLASTOMA CELLS. Cytokine, 1998, 10, 586-595.	3.2	11
29	A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2012, 61, 783-788.	4.2	11
30	Performance characteristics of EUS-FNA biopsy for adrenal lesions: A meta-analysis. Endoscopic Ultrasound, 2019, 8, 180.	1.5	11
31	Cyclic nucleotide changes in murine lymphocytes following thymosin incubation in vitro. Immunopharmacology, 1979, 1, 89-101.	2.0	10
32	Localization of Thymosin $\hat{l}\pm 1$ Production to Thymus Medullary Epithelial Cells by Use of Monoclonal Antibodies. Hybridoma, 1987, 6, 47-59.	0.6	10
33	Thymus-Derived Peptides in the Treatment of Viral Chronic Hepatitis. Digestive Diseases, 1996, 14, 362-370.	1.9	10
34	Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. Journal of Interferon and Cytokine Research, 2016, 36, 291-301.	1.2	10
35	The thymus AIDS connection: Thymosin in the diagnosis and treatment of individuals at risk for AIDS. BioEssays, 1984, 1, 63-69.	2.5	8
36	Identification of immunoreactive forms of thymosin $\hat{l}\pm 1$ in serum and supernatants by combining HPLC and RIA. International Journal of Immunopharmacology, 1992, 14, 1267-1278.	1.1	8

#	Article	IF	CITATIONS
37	Thymosin in the Staging and Treatment of HLTV-III Positive Homosexuals and Hemophiliacs with AIDS-Related Immune Dysfunction. Advances in Experimental Medicine and Biology, 1985, 187, 129-140.	1.6	7
38	Identification and distribution of thymosin alpha 1-like immunoreactivity. Developmental and Comparative Immunology, 1988, 12, 397-402.	2.3	5
39	Zadaxin (thymosin $\hat{l}\pm 1$ ) for the treatment of viral hepatitis. Expert Opinion on Investigational Drugs, 1999, 8, 281-287.	4.1	5
40	Preclinical studies with IRX $\hat{a}$ and thymosin $\hat{l}$ in combination therapy. Annals of the New York Academy of Sciences, 2010, 1194, 162-168.	3.8	4
41	Abnormally elevated thymosin $\hat{l}\pm 1$ levels in the acquired immunodeficiency syndrome (AIDS). Clinical Immunology Newsletter, 1983, 4, 126-128.	0.1	3
42	Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C. Hepatic Medicine: Evidence and Research, 2017, Volume 9, 13-16.	2.5	3
43	Thymosin $\hat{l}\pm 1$ does not promote growth or oncogenic transformation. International Journal of Immunopharmacology, 1996, 18, 321-327.	1.1	2
44	Variations in Screening Adenoma Detection Rate by Specialty of Physicians in a Predominately African American Population. Cureus, 2019, 11, e6003.	0.5	2
45	Diagnostic Assays for Human Immunodeficiency Virus Infection and for Clinical Progression by Use of Synthetic p17 Peptide Epitopes. Monographs in Virology, 1990, 18, 74-90.	0.6	O
46	Serum cross-reactive thymosin a1 levels in rats during induction of mammary carcinoma with 7,12-dimethylbenz[a]anthracene: short- and long-term effects. Cancer Letters, 1993, 69, 187-189.	7.2	0
47	Overlapping molecular signaling of IRX-2 and Ta1 resulting in synergistic biological activity. Expert Opinion on Biological Therapy, 2018, 18, 85-88.	3.1	O